Outlook Therapeutics, Inc. Class Action Lawsuit - OTLK

The filed complaint alleges that Outlook Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) there was a lack of substantial evidence supporting the Company's lead product candidate, ONS-5010, as a treatment for wet age-related macular degeneration; (ii) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls and other manufacturing issues for ONS-5010, which remained unresolved at the time the ONS-5010 biologics license application (“BLA”) was resubmitted to the U.S. Food and Drug Administration ("FDA"); (iii) as a result of all the foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its present form; (iv) accordingly, ONS-5010’s regulatory and commercial prospects were overstated; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the OTLK class action lawsuit, you must have incurred a loss on shares of Outlook purchased during the class period listed above.

If you suffered a loss in Outlook during the relevant time frame or pursuant to the relevant offering(s), you have until January 2, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.